Table 4 Multivariate Cox analyses of PFS and OS in training and validation cohorts

PFS

 Gender (Male vs. Female)

0.704(0.458–1.082)

0.110

-

-

 Age (≤ 55 vs. > 55)

1.424(0.973–2.084)

0.069

-

-

 T stage (T1-T2 vs. T3-T4)

0.962(0.615–1.506)

0.866

-

-

 N stage (N0-N1 vs. N2-N3)

-

-

1.310(0.720–2.385)

0.376

 TNM stage (I-II vs. III-IVa)

2.680(1.314–5.466)

0.007

1.536(0.664–3.555)

0.316

 EBV DNA (negative vs. positive)

2.625(1.737–3.966)

 < 0.001

3.237(1.870–5.604)

 < 0.001

 LA (≤ 80.17 vs. > 80.17)

0.463(0.318–0.675)

 < 0.001

0.392(0.241–0.637)

 < 0.001

OS

 Age (≤ 55 vs. > 55)

3.163(1.860–5.380)

 < 0.001

2.488(1.244–4.974)

0.010

 T stage (T1-T2 vs. T3-T4)

0.788(0.419–1.481)

0.459

1.815(0.783–4.206)

0.165

 TNM stage (I-II vs. III-IVa)

7.890(1.770–35.170)

0.007

2.698(0.558–13.035)

0.217

 EBV DNA (negative vs. positive)

1.950(1.083–3.510)

0.026

3.703(1.659–8.263)

0.001

 LA (≤ 80.17 vs. > 80.17)

0.340(0.182–0.633)

0.001

0.206(0.089–0.479)

 < 0.001